Therapeutic Plasma Exchange Market 2026 – 2035

The therapeutic plasma exchange market size in the world is estimated to be USD 1.84 billion in 2025 and forecasted to rise to between USD 1.98 billion in 2026 and USD 4.12 billion in 2035 with a CAGR of 7.6% between 2026 and 2035. The increasing clinical use of therapeutic plasma exchange across an ever-expanding array of neurological, autoimmune, hematological, and renal diseases due to the mounting clinical evidence of therapeutic efficacy of TPE as a first-line or complementary therapy in diseases including neuromyelitis optica spectrum disorder, anti-NMDA receptor encephalitis, myasthenia gravis, thrombotic thrombocytopenic purpura, and ANCA-associated vasculitis, the growing global incidence of autoimmune and neuroinflammatory conditions that represent the most rapidly expanding segment of TPE clinical indications, the progressive expansion of TPE-capable clinical infrastructure in developing nations as healthcare systems invest in the apheresis technology required to deliver this specialized therapeutic modality, the rising adoption of novel apheresis technologies including selective adsorption columns and membrane-based plasma separation enabling more targeted plasma purification than conventional centrifugation plasma exchange, and the expanding evidence base supporting TPE in emerging indications including COVID-19-associated cytokine storm, hypertriglyceridemia-induced pancreatitis, and certain drug intoxication scenarios collectively drive robust and sustained market growth throughout the forecast period.

Market Highlight

• North America was a market leader with 38% market share in the therapeutic plasma exchange in 2025.

• The most rapid CAGR of 10.2% is anticipated to be in Asia Pacific in the period of 2026 to 2035.

• By product line, the disposable and consumables market segment took up nearly 44% of the market share in the year 2025.

• By product type, the highest CAGR of 8.4% is observed within the segment of the apheresis devices between the years 2026 and 2035.

• By indication, the neurological disorders segment took the largest market share of 34% in 2025, and the autoimmune disorders segment will record the highest CAGR of 10.8% in the next projected period, which is known to be between 2026 and 2035.

• By end-user, the hospitals and clinics segment will have the largest market share of 68% in 2025, with the specialty treatment centers segment projected to have the fastest CAGR of 9.6% in 2026-2035.

Significant Growth Factors

The Therapeutic Plasma Exchange Market Trends present significant growth opportunities due to several factors:

• Expanding Neurological and Autoimmune Indications Driving Clinical Adoption Growth:

The most significant growth driver of TPE market is the progressive diversification of the clinical indication portfolio of TPE which is fuelled by the accelerating scientific awareness of antibody-mediated neurological disorders, by the clinical validation of TPE in newly identified autoimmune diseases and by the growing acceptance of immune dysregulation as a pathogenic mechanism across the broader range of patients with an antibody phenotype with whom a neurologist or a rheumatologist will find themselves increasingly willing to consider treatment with TPE since each new clinical indication of TPE introduces a new patient population into the treatment eligible population The treatment landscape of neuromyelitis optica spectrum disorder - changed by the description of anti-aquaporin-4 and anti-MOG antibodies as the pathogenic agents that cause the severe attacks of NMOSD on the optic nerve and the spinal cord— has made TPE a first-line treatment of acute attacks with published evidence of better recovery outcomes in the acute NMOSD attacks with TPE versus high-dose corticosteroids alone, establishing a well-known and expanding NMOSD TPE indication that is expanding along with increased NMOSD diagnostic rates as neurologists progressively test to detect the disease-defining antibodies.

The anti-NMDA receptor encephalitis indication, the most prevalent autoimmune encephalitis diagnosis in the world, following the characterization of anti-NMDAR antibodies by the research group led by Josep Dalmau, has established TPE as a foundation of first-line immunotherapy in combination with intravenous corticosteroids and intravenous immunoglobulin in published treatment regimens, the published case series and cohort retrospective studies represent the evidence base underlying increased clinical usage. The American Society for Apheresis issues periodic updates to its evidence-based Guidelines to the Use of Therapeutic Apheresis in Clinical Practice - the most recent update being in 2023 - the list of over 80 clinical conditions receiving the highest level of evidence to indicate TPE is increasing, with the increasing number of clinical conditions reaching either Category I or Category II levels of evidence being the regulatory and clinical validation that drives the adoption of clinical practice and the expansion of health system reimbursement coverage.

The prevalence of autoimmune diseases worldwide, estimated at about 58% of the population in developed countries as published epidemiology, and the increasing rates of incidence of multiple autoimmune conditions such as multiple sclerosis, neuromyelitis optica, myasthenia gravis, and systemic lupus erythematosus (Latin, n., 2011), forms the population growth of patients that drives structural demand growth on TPE services other than technology or clinical practice change-driven growth. The increasing knowledge of antibody-mediated pathogenicity processes - facilitated by the development of autoantibody characterization methods such as cell-based tests and live cell imaging that detect hitherto undetected pathogenic immunoglobulins - is steadily transforming hitherto idiopathic or seronegative conditions into named autoantibody-positive disorders in which the TPE immunoglobulin removal mechanism can be logically used to target therapeutically, which is continually expanding the TPE indication repertoire as autoantibody characterization science advances.

• Thrombotic Thrombocytopenic Purpura Burden and Emergency TPE Infrastructure Driving Market:

The clinical management of thrombotic thrombocytopenic purpura - a hematological crisis precipitated by severe deficiency of ADAMTS13 causing platelet-rich thrombus formation in the microvasculature with disastrous ischemic consequences affecting the brain, kidney, and heart - is the most life pathologically urgent TPE indication and the clinical use that most eloquently illustrates the invaluable nature of TPE in clinical therapy, which supports the maintenance of TPE-capable emergency infrastructure at tertiary medical facilities around the world that creates Unrestrained TTP mortality. It reaches 90% in a few days, and immediate commencement of TPE lowers the mortality rate to less than 10–15% in published contemporary series - a treatment effect of remarkable scale and the main cause of emergency TPE capacity by hematological emergency departments.

The increased international acceptance of ADAMTS13 testing as the diagnostic standard in TTP differentiation over TTP-mimicking disorders - making possible the rapid confirmation-based initiation of TPE as opposed to the empirical plasma exchange in suspected TTP - is enhancing the management of TTP, and is influencing the demand to combine the high-speed ADAMTS13 assay capability with the immediately available TPE infrastructure that is being purchased by tertiary hospitals to offer contemporary standards of TTP management. The growing understanding of immune TTP as a relapsing disorder, with a minority of TTP patients having gone through a series of disease relapses during their lifespan such that TPE treatment is necessary, creates a longitudinal pattern of TPE use by the individual patient that persists as the surviving population of TTP patients continues to relapse in disease states that necessitate TPE treatment.

The invention of caplacizumab - the anti-VWF nanobody licensed in 2019 which dramatically decreases TTP-related mortality and refractoriness when administered with TPE - is an important advance in TTP treatment whose application in combination with TPE instead of replacing TPE has heightened resource intensity in TTP treatment and the combination of caplacizumab plus TPE has become the preferred treatment modality in advanced centers and is driving a rise in the per-episode cost and complexity of TTP treatment that has become the incentive to continue investing in.

What are the Major Advances Changing the Therapeutic Plasma Exchange Market Today?

• Selective Apheresis Technology Development Beyond Conventional Plasma Exchange:

The emergence and growing clinical use of selective apheresis technologies - wherein the plasma separation step of traditional TPE is followed by flow of the separated plasma through special adsorption columns or secondary filtration membranes that selectively remove specific pathogenic molecules and leave most plasma proteins untouched, which provides both clinical and economic advantages, removing the adverse event of replacement fluids and greatly decreasing consumption of exogenous replacement fluids, which is a major cost factor of traditional TPE procedures.

Immunoadsorption the most clinically established selective apheresis technology, which employs protein A or specific antigen columns to selectively remove immunoglobulins during the treatment of immunoglobulin-dominated conditions and avoids the non-specific removal of coagulation factors, complement proteins, and other clinically beneficial regulatory immunoglobulins that the bulk plasma replacement in conventional TPE results in, has been widely used in European centres and is demonstrated in published comparative studies to be effective in removing immunoglobulins selectively to Another selective technology that has demonstrated more specific pathogenic factor removal than the conventional bulk plasma exchange is the cascaded filtration method, where separated plasma is filtered through a second membrane filter that retains high-molecular-weight immunoglobulins and immune complexes but excludes albumin and lower-molecular-weight proteins. Fresenius medical care Evasorb tryptophan apheresis column to treat multiple sclerosis and other neurological diseases, Miltenyi Biotec's CliniMACS CD34+ selection system used to purify stem cells, and Exocel Biosystems' LDL apheresis technology are some commercial applications of selective apheresis expanding the therapeutic plasma purification field beyond standard TPE.

Investment in more selective apheresis technologies, whose clinical relevance is guided by the clinical rationale of selectivity (immunoglobulin A4 selectivity - avoiding clearing of desirable plasma proteins, such as coagulation factors, complement proteins, and albumin, and vice versa, in the clearance of pathogenic immunoglobulins), is becoming a focus of research and development efforts in more selective apheresis technologies where commercial development is steadily increasing the number of treatment options available to clinicians managing antibody-mediated conditions.

• Membrane-Based Plasma Separation Advancing as Alternative to Centrifugation:

Another technical method of delivering TPE procedure, called membrane-based plasma separation technology, in which blood is flowed through a hollow fiber membrane with a specific pore size allowing centrifugal-free plasma to flow through, but preventing centrifugal-free cellular blood components from passing through, is becoming an increasingly popular alternative technology to centrifugation-based plasma separation due to its operational benefits such as easier equipment maintenance, compatibility with single-needle access, and reduced initial cost of equipment compared to centrifugation-based plasma separation systems and with similar plasma separation efficiency to most clinical TPE Membrane plasma separators Asahi Kasei Medical, Fresenius Medical Care, and B. Braun are made, which have gained widespread commercial acceptance especially in Asia and Europe where membrane-based TPE has been a preferable choice to centrifugation-based systems that prevail in the North American apheresis practice setting, with similar clinical experience reported on the two membrane and centrifugation TPE strategies of similar clinical outcome, adverse event rates, and plasma removal volumes.

The single needle accessibility of membrane based system - which allows TPE procedures to be performed using a single peripheral vein or central venous access catheter lumen - offers a clinical benefit in patients with limited venous access where traditional centrifugation systems would require parallel draw and return flows, necessitating the use of two needles which causes patient discomfort as well as difficulties in access. The combination of membrane plasma separators with online cascade filtration modules - resulting in combined plasma separation and selective purification systems in one procedure circuit - is allowing complex selective plasma purification protocols to be run in membrane-based platforms whose modular architecture can be readily extended to secondary filtration without the dedicated apheresis workstation that centrifugation-based selective apheresis needs.

• Digital Integration and Procedure Automation Advancing Apheresis System Capabilities:

The further development of Apheresis Systems: The further integration of digital connectivity, automated procedure optimization and clinical decision support into therapeutic apheresis systems - developing intelligent platforms where procedure volumes are automatically calculated based on patient weight and hematocrit, where circuit pressures and flow rates are continually monitored using automated alarm and correction response, where comprehensive procedure documentation is generated to assure quality and meet regulatory requirements, and where they are interconnected with hospital information systems through integration of electronic procedure records - continue to enhance the safety of TPE procedures, offload nursing personnel, and provide Apheresis The modern apheresis workstations such as the Spectra Optia of Terumo BCT, the COM. TEC of Fresenius Kabi and the Aurora apheresis devices of Haemonetics have designed more complex software-driven procedure automation to maximize the efficiency of plasma separation, delivery of anticoagulating agents and delivery of replacement fluids based on real-time monitoring of the circuit, which has reduced manual adjustment interventions that were necessary with older generation systems and has also allowed less experienced operators to achieve the same quality of the procedure.

The clinical decision support applications such as automated calculation of plasma volumes to exchange depending on patient demographics and indication-specific evidence-based targets, anticoagulant dosing recommendations depending on patient coagulation parameters, and replacement fluid composition optimization depending on available evidence on specific indications are gradually incorporating clinical expertise into apheresis system software allowing practitioners with different levels of apheresis experience to deliver procedures of an established quality. Remote monitoring feature - allowing apheresis equipment manufacturers to remotely troubleshoot system malfunctions, issue software updates, and provide technical support to equipment without the presence of on-site technicians, equipment downtime at hospitals that lack at least one apheresis technical support person on site at all times is decreasing equipment downtime at both developed and developing market centers, as well as equipment reliability and availability.

The comprehensive procedure data that are recorded by today's apheresis systems such as real time flow rates, pressures, volumes, anticoagulation delivery, and adverse events documentation are producing structured procedure datasets that quality improvement programs in major apheresis centers are evaluating to identify practice patterns correlated with excellent outcomes and few adverse events to drive evidence-based protocol optimization that enhances the clinical value of TPE delivery across populations of patients.

Category Wise Insights

By Product Type

Why Do Disposables & Consumables Lead the Market?

Disposables and consumables present the highest product type segment with a figure of about 44% of the total market share in 2025; the basic revenue model of the therapeutic apheresis market, i.e. one complete single-use procedure set of apheresis separation circuit, blood tubing, plasma collection bag, needle sets, and plasma filtration membrane or adsorption column, is required to accomplish a single TPE procedure, the result of which is a high-frequency, procedure-volume-proportional consumable revenue stream that is of significant value in terms of The single-use procedure set model which is mandatory due to patient safety considerations due to the infection control demands of blood-handling medical procedures as well as the inability to properly clean and re-sterilize complex multi-component apheresis circuits creates an inherent form of recurring revenue model in which a single installed apheresis workstation is a source of continuous consumable revenue proportional to the rate of procedure utilization, and with apheresis workstations typically performing 200 at the lowest extreme to 500 at the most extreme per installation of apheresis circuits, representing The second largest category of consumable item cost is replacement fluids, including the 5% albumin and fresh frozen plasma that substitutes the separated plasma of the patient during the traditional TPE and the normal saline that serves as prime and carrier fluid, which is the second largest consumable cost of this category, as albumin costs premium pricing ranges of USD 80-USD 200 per 250 ml bottle and 2-4 liters of albumin solution are needed per TPE procedure in adults. Apheresis devices will grow the most (CAGR of 8.4) between 2026 and 2035 with the stimulus of TPE capability growth in developing countries of new device purchases to create apheresis programs, replacement of older devices at existing programs with new automation and digital connectivity functionality, and new selective apheresis platforms that need new capital investment equipment beyond the centrifugation workstations that already own the established programs.

By Indication

Why Do Neurological Disorders Lead the Market?

The largest indication segment in the market is approximately 34% of total market share in 2025, which is the neurological disorders, indicating the concentration of ASFA Category I and Category II TPE evidence in a variety of neurological conditions including GuillainBarre syndrome, myasthenia gravis exacerbation, neuromyelitis optica spectrum disorder attacks, anti-NMDAR encephalitis, as well as chronic inflammatory demyelinating polyneuropathy, indicating a significant and growing patient population utilizing TPE services in neurology- Guillain-Barré syndrome — the acute autoimmune peripheral neuropathy due to antibodies against anti-gangliosides against peripheral myelin - is the oldest indication of neurological TPE with the most rigorous randomized controlled trial evidence base, including landmark trials showing the superiority of TPE in reducing ventilator dependency duration and functional outcomes 6 months post-intervention, which serves as the reference to a level of evidence necessary to establish the standard of care in neurological indications and led to the development of an infrastructure to support clinical development that subsequently supported the expansion of neurological indications.

The fastest growing segment is the autoimmune disorders segment with a CAGR of 10.8% between 2026 and 2035 due to the increase in the number of known antibody-mediated autoimmune disorders - including newly described inflammatory arthropathies to systemic autoimmune disorders—with new autoantibody associations. TPE has a mechanism of removing immunoglobulins which gives it a mechanistic rationale, and the clinical evidence supporting therapeutic benefit is increasing, as well as the rising familiarity of the rheumatology and immunology community's familiarity with apheresis as a treatment tool whose application they are progressively considering across their antibody-positive patient populations.

By End-User

Why Do Hospitals & Clinics Lead the Market?

The largest end-user segment is hospitals and clinics which has a market share of about 68% in 2025 as the concentration of TPE-capable system is in tertiary hospital settings - the clinical complexity of conditions that a patient may require TPE, the specialty physician attention, the blood banking and laboratory support that would assist in management of the replacement fluid and the observation of the procedure, and the back-up life-critical care that is necessary to manage procedures if adverse events occur in patients with medically complex conditions makes the most of TPE delivery be in hospitals rather than Academic medical Centers/Institutions - as the primary TPE providers in both the delivery of patients locally (where they represent a source of TPE presentation) and in the referral center (regions where patients are specifically referred to receive TPE capability) - are the same highest volume individual TPE providers in the world, and produce the largest volume of clinical research papers which support the expansion of the evidence base supporting the expansion of TPE indications. The fastest growth rate of 9.6% between 2026 and 2035 is in specialty treatment centers owing to the gradual emergence of specialty apheresis centers and neurology-specialty centers that will focus TPE capability in outpatient care compared to episodic treatment based in hospitals.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America therapeutic plasma exchange market size is estimated at USD 699 million in 2025 and is projected to reach approximately USD 1.49 billion by 2035, with a CAGR of 7.9% from 2026 to 2035.

Why Did North America Dominate the Market in 2025?

In 2025, North America dominates about 38-percent of world market share, an indication that the United States is the most technologically advanced and highest volume therapeutic apheresis market, with the highest concentration of dedicated apheresis programs, the broadest coverage of health insurance reimbursement of approved TPE indications under Medicare and with major commercial payers and the highest density of board-certified apheresis specialists being trained in American Board of Internal Medicine and American Society for Apheresis fellowship programs.

The extensive Medicare coverage of ASFA-classified TPE indications offered by the United States to fund the apheresis procedure and the replacement fluid expenses incurred under established CPT codes is what provides the health insurance framework that allows broad-based clinical implementation of TPE in the U.S. hospitals that do not have the highest resource endowment and that have defined reimbursement pathways that provide the initial infrastructure and the future economics of the procedure. The world's leading professional association for apheresis medicine, the American Society of Apheresis, based in the United States, publishes the globally recognized Guidelines to Therapeutic Apheresis that specify evidence-based categories of indication and clinical best practice, and the U.S. practitioners are given earlier access and familiarity with these guidelines, facilitating more pervasive TPE clinical adoption as compared to markets in which awareness of the evidence base is not so systematic.

Why is Europe a Strategically Important Market?

The European therapeutic plasma exchange market is predicted to be about USD 478 million in 2025 and is anticipated to grow to about USD 1.03 billion in 2035 with a CAGR of 7.9. Europe is a market of core strategic value supported by the fact that Germany is the largest TPE market in Europe - with the most concentration of dedicated apheresis centers in European countries, key statutory health insurance coverage of recognized TPE indications under the German GKV reimbursement system, and the strong presence of leading apheresis equipment manufacturers Fresenius Kabi and B. Braun in the development of the apheresis market in Europe. the Scandinavian countries with extensive coverage of the health system supporting development of high-quality apheresis programs and the UK with a strong system The professional education and evidence dissemination infrastructure offered by the European apheresis medicine community, through the European Apheresis Academy and the International Society for Apheresis, has facilitated the consistent TPE clinical deployment in accordance with modern evidence standards across the European healthcare systems with varied national health technology assessment systems. The ANSM regulatory framework of therapeutic apheresis procedures and the development of the apheresis specialty of the French Society of Blood Transfusion are other European markets that have contributed significantly to the market along with Germany and the United Kingdom.

Why is Asia Pacific the Fastest-Growing Market?

The most rapidly growing regional market is Asia Pacific with a projected CAGR of 10.2% between 2026 and 2035 based on its very sophisticated infrastructure of apheresis medicine with Japan representing the most developed apheresis market in Asia and with the Japanese Society of Apheresis making major contributions to the global apheresis clinical research the rapidly expanding tertiary hospital apheresis capability in China as the major Asian academic hospitals invests in apheresis programs, and the rapidly growing middle-income population in the Asia Pacific region now accessing tertiary specialist healthcare The original contribution of Japan to apheresis medicine and the broader Asia Pacific region's rapidly growing middle-income population accessing tertiary specialist healthcare services at rates that are progressively including the specialized TPE services that were previously available only at the most resource-rich institutions. Japan's unique contribution to apheresis medicine — including the development and commercial deployment of LDL apheresis for familial hypercholesterolemia, the innovation of rheopheresis for age-related macular degeneration, and the early adoption of adsorption column-based selective apheresis technologies — reflects Japan's position as the Asia Pacific leader in apheresis technology adoption and clinical application breadth that extends well beyond the neurological and hematological TPE indications dominant in Western markets.

Why is the Middle East & Africa Region an Emerging Market?

The LAMEA region displays an increasing demand for therapeutic plasma exchange (TPE) fuelled by the established formulation of the tertiary health care system of Saudi Arabia and the UAE, which respectively feature King Faisal Specialist Hospital, Sheikh Khalifa Medical City and Cleveland Clinic Abu Dhabi, operating full-fledged apheresis programs at international standards. They treat known conditions (such as thrombotic thrombocytopenic purpura, or TTP, and neurological conditions) and emerging conditions such as neuromyelitis optica spectrum disorder, or NMOSD, and autoimmune encephalitis. Apheresis is also available in Israel in Hadassah Medical Center, Sheba Medical Center, and major Israeli university hospitals. Brazil is developing its apheresis infrastructure in major academic centers such as Hospital das Clínicas da Unicamp, Hospital das Clínicas de São Paulo, and Hospital Albert Einstein which act as regional referral centers for TPE in South America.

Top Players in the Market and Their Offerings

• Terumo BCT Inc.

• Fresenius Kabi AG

• Haemonetics Corporation

• B. Braun Melsungen AG

• Asahi Kasei Medical Co. Ltd.

• Miltenyi Biotec GmbH

• Nikkiso Co. Ltd.

• Kaneka Corporation

• Hemacare Corporation (Charles River Laboratories)

• Cerus Corporation

• Scinai Immunotherapeutics

• Others

Key Developments

The market has undergone significant developments as industry participants seek to advance selective apheresis technology capabilities, expand neurological indication clinical evidence, and respond to the growing global clinical demand for therapeutic plasma exchange across established and emerging indication portfolios.

• In September 2024: Terumo BCT launched their Spectra Optia Apheresis System Software Version 12.0. The new software has an automated optimization algorithm that 1) continuously adjusts inlet flow, centrifuge speed, and plasma removal rate based on real time hematocrit and platelet surveillance data, and 2) maintains separation efficiency throughout the procedure.

• In February 2025: Fresenius Kabi announced the commercial launch of it. It uses a dual-column protein-A-coated regenerable adsorption circuit for removing IgG immunoglobulins from plasma. The system has a cycle regeneration of 3-5 during a given session that can lower IgG 80-90% compared with the 50-65% achieved with conventional TPE at the same volume of plasma.

The Therapeutic Plasma Exchange Market is segmented as follows:

By Product Type

• Apheresis Devices (Centrifugation-Based, Membrane-Based, Selective Adsorption Systems)

• Disposables & Consumables (Apheresis Sets, Tubing, Needles, Plasma Filters)

• Replacement Fluids (Albumin, Fresh Frozen Plasma, Saline Solutions)

• Other Product Types (Anticoagulants, Adsorption Columns, Software)

By Indication

• Neurological Disorders (Guillain-Barré Syndrome, NMOSD, Myasthenia Gravis, Anti-NMDAR Encephalitis, CIDP)

• Hematological Disorders (Thrombotic Thrombocytopenic Purpura, Hyperviscosity Syndrome, Sickle Cell Disease)

• Renal Disorders (ANCA-Vasculitis, Anti-GBM Disease, Focal Segmental Glomerulosclerosis)

• Autoimmune Disorders (SLE, Rheumatoid Arthritis, Pemphigus Vulgaris)

• Metabolic Disorders (Hypertriglyceridemia-Induced Pancreatitis, Familial Hypercholesterolemia)

• Other Indications (Drug Intoxication, Transplant Rejection, Cytokine Storm)

By End-User

• Hospitals & Clinics (Academic Medical Centers, General Hospitals)

• Dialysis Centers (In-Center Hemodialysis Units with Apheresis Capability)

• Specialty Treatment Centers (Dedicated Apheresis Units, Neurology Centers)

• Other End-Users (Research Institutes, Military Healthcare)

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America